Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Vos, S. Dakhil, P. Mclaughlin, M. Saleh, R. Belt, C. Flowers, M. Knapp, L. Hart, D. Patel-Donnelly, M. Glenn, S. Gregory, C. Holladay, A. Boral, Tracy Zhang, A. Goy (2005)
Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.Blood, 106
T. Buchholz, R. Theriault, J. Niland, M. Hughes, R. Ottesen, S. Edge, M. Bookman, J. Weeks (2006)
The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 3
P. Sonneveld, W. Putten, H. Holte, D. Biesma, M. Marwijk-Kooy, M. Kramer, P. Wijermans, Monique Steijaert, P. Huijgens, M. Eriksson (2005)
Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.Blood, 106
H. Lueck, G. Minckwitz, A. Bois, I. Schrader, J. Huober, V. Heilmann, M. Beckmann, A. Stähle, C. Jackisch, C. Marth, B. Richter (2006)
Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
S. Corson (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomesJournal of Minimally Invasive Gynecology, 13
H. Hochster, Lowell Hart, R. Ramanathan, J. Hainsworth, Eric Hedrick, B. Childs (2006)
Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
S. Al-Batran, J.T. Hartmann, S. Probst (2006)
A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin versus fluorouracil, leucovrin and cisplatin [abstract no. LBA4016]J Clin Oncol, 24
N.P. Shah, P. Rousselot, R. Pasquini (2006)
Dasatinib vs high dose imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib: results of CA180017 START-R randomized trial [abstract no. 6507]J Clin Oncol, 24
M.P. Mehta, R. Gervais, P. Chabot (2005)
Motexafin gadolinium combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer patients with brain metastases: results of a phase III trial [abstract no. 7014]Blood, 106
Yoon-Koo Kang, W. Kang, D. Shin, J. Chen, J. Xiong, J. Wang, M. Lichinitser, M. Philco, T. Suarez, J. Santamaría (2006)
Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
F.M. Calais Silva, F. Calais Silva, A. Bono (2006)
Phase III intermittent MAB vs continuous MAB [abstract no. 4513]J Clin Oncol, 24
A. Burnett, M. Baccarani, P. Johnson, J. Yin, N. Russell (2006)
Clofarabine in previously untreated elderly (>65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Starosławska, T. O'Toole, S. Kong, L. Moore (2006)
A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
A. Dmoszyńska, Raouf Fetni, Y. Wang, M. Belkaci, C. Sirard, M. Goldberg, J. Mayer, T. Robak, A. Skotnicki, P. Hillmen (2006)
Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
A. Hochhaus, M. Baccarani, C. Sawyers, A. Nagler, T. Facon, S. Goldberg, F. Cervantes, R. Larson, M. Voi, R. Ezzeddine, H. Kantarjian (2005)
Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.Blood, 106
M. Sugrue, M. Kozloff, J. Hainsworth, S. Badarinath, A. Cohn, Patrick Flynn, R. Steis, W. Dong, S. Sarkar, A. Grothey (2006)
Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
R. Labianca, I. Floriani, E. Cortesi (2006)
Alternating versus continuous FOLFIRI in advanced colorectal cancer: a randomized GISCAD trial [abstract no. 3505]J Clin Oncol, 24
F. Demarinis, S. Paul, N. Hanna, T. Tsao, S. Adachi, H. Lim (2006)
Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
Y. Kang, W.K. Kang, D.B. Shin (2006)
Randomized phase III trial of capecitabine/ cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients with advanced gastric cancer: efficacy and safety results [abstract no. LBA4018]J Clin Oncol, 24
S.V. Rajkumar, M. Hussein, J. Catalano (2006)
A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dex-amethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma [abstract no. 7517]J Clin Oncol, 24
F. Maindrault-Goebel, G. Lledo, B. Chibaudel (2006)
OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer. A GERCOR study [abstract no. 3504]J Clin Oncol, 24
N. Shah, P. Rousselot, R. Pasquini, N. Hamerschlak, J. Hołowiecki, B. Gerard, D. Dejardin, H. Kantarjian (2006)
Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
F. Guilhot, J. Apperley, N. Shah, Dong-Kee Kim, A. Grigg, S. Cheng, M. Iyer, Jordi Cortés (2005)
A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.Blood, 106
R.E. Coleman (2006)
Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial [abstract no. 511]J Clin Oncol, 24
L. Fehrenbacher, Vincent O'Neill, C. Belani, P. Bonomi, Lowell Hart, O. Melnyk, Alan Sandler, D. Ramies, R. Herbst (2006)
A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
Salah-Eddin Al-Batran, J. Hartmann, S. Probst, R. Hofheinz, J. Stoehlmacher, H. Schmalenberg, S. Hollerbach, Gunter Schuch, N. Homann, E. Jäger (2006)
A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
A. Bardia, C. Loprinzi, M. Goetz (2006)
Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
A. Dmoszynska, R. Fetni, Y. Wang (2006)
Cytogenetic correlation with efficacy on alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia [abstract no. 6601]J Clin Oncol, 24
R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski, O. Rixe, S. Oudard, S. Kim, C. Baum, R. Figlin (2006)
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC), 24
S. Land, D. Wickerham, J. Costantino, M. Ritter, V. Vogel, Myoungkeun Lee, E. Pajon, J. Wade, S. Dakhil, James Lockhart, N. Wolmark, P. Ganz (2006)
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.JAMA, 295 23
R.C. Coombes, R. Paridaens, J. Jassem (2006)
First mature analysis of the Intergroup Exemestane Study [abstract no. LBA527]J Clin Oncol, 24
C. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki, V. Ganju, M. Jeffery, J. Schultz, D. Richards, B. Wang, M. Morrison (2006)
A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
S. Rajkumar, Mohamad Hussein, John Catalano, W. Jedrzejcak, Svetlana Sirkovich, Marta Olesnyckyj, Zhinuan Yu, R. Knight, J. Zeldis, J. Bladé (2006)
A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
S.R. Berry, D. Cunningham, M. Michael (2006)
Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC: first B.E.A. trial [abstract no. 3534]J Clin Oncol, 24
S. Berry, David Cunningham, Michael Michael, M. Dibartolomeo, Fernando Rivera, A. Kretzschmar, M. Mazier, B. Lutiger, E. Vancutsem (2006)
Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC-First B.E.A.Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
M. Talpaz, P. Rousselot, Dong-Kee Kim, F. Guilhot, S. Corm, E. Bleickardt, R. Zink, G. Rosti, S. Coutre, C. Sawyers (2005)
A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.Blood, 106
V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade, A. Robidoux, R. Margolese, J. James, S. Lippman, C. Runowicz, P. Ganz, S. Reis, W. McCaskill-Stevens, L. Ford, V. Jordan, N. Wolmark (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.JAMA, 295 23
R. Coombes, R. Paridaens, Jacek Jassem, C.J.H. Velde, Thierry Delozier, S Jones, Emma Hall, L. Kilburn, C. Snowdon, J. Bliss (2006)
First mature analysis of the Intergroup Exemestane Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
D. Wickerham, J. Costantino, V. Vogel, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, W. McCaskill-Stevens, N. Wolmark (2006)
The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
W. Regine, K. Winter, R. Abrams, H. Safran, J. Hoffman, A. Konski, A. Benson, J. Macdonald, C. Willett, T. Rich (2006)
RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
T. Kang, C. Lowe, M. Sekeres (2006)
Thalidomide use and digital gangrene.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 33
C. Fuchs, J. Marshall, E. Mitchell (2006)
A randomised trial of first-line irinotecan/ fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C) [abstract no. 3506]J Clin Oncol, 24
W.F. Regine, K.W. Winter, R. Abrams (2006)
RTOG 9704: a phase III study of adjuvant pre and post chemoradiation 5-FU vs. gemcitabine for resected pancreatic adenocarcinoma [abstract no. 4007]J Clin Oncol, 24
F. Guilhot (2005)
Mutation detection in CML: is it a useful tool?Blood, 106
M. Sugrue, M. Kozloff, J. Hainsworth (2006)
Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy [abstract no. 3535]J Clin Oncol, 24
R. Coleman (2006)
Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
A.K. Burnett, M. Baccarani, P. Johnson (2006)
Clofarabine in previously untreated elderly (greater than 65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy [abstract no. 6513]J Clin Oncol, 24
O. Ottmann, G. Martinelli, H. Dombret, H. Kantarjian, A. Hochhaus, B. Simonsson, A. Aloe, A. Apanovitch, N. Shah (2005)
A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.Blood, 106
R.J. Motzer, T.E. Hutson, P. Tomczak (2006)
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [abstract no. LBA3]J Clin Oncol, 24
H.S. Höchster, L.L. Hart, R.K. Ramanathan (2006)
Safety and efficacy of oxaliplatin/ fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: final analysis of the TREE-study [abstract no. 3510]J Clin Oncol, 24
E. Hedrick, M. Kozloff, J. Hainsworth, S. Badarinath, A. Cohn, P. Flynn, W. Dong, S. Suzuki, M. Sugrue, A. Grothey (2006)
Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
A. Ko, E. Dito, B. Schillinger, A. Venook, E. Bergsland, M. Tempero (2006)
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 3
David Cunningham, S. Rao, N. Starling, T. Iveson, Marianne Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. Norman (2006)
Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
R. Labianca, I. Floriani, E. Cortesi, L. Isa, A. Zaniboni, M. Marangolo, L. Frontini, S. Barni, G. Beretta, A. Sobrero (2006)
Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
D. Weber, Christine Chen, R. Niesvizky, Michael Wang, A. Belch, E. Stadtmauer, Zhinuan Yu, Marta Olesnyckyj, J. Zeldis, R. Knight (2006)
Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
H. Lueck, G.V. Minckwitz, A. Bois (2006)
Epirubicin/paclitaxel vs. capecitabine/ paclitaxel in first-line metastatic breast cancer: a prospective, randomized multicentre phase III study of the AGO breast cancer study group [abstract no. 517]J Clin Oncol, 24
T. Facon, J. Mary, J. Harousseau (2006)
Superiority of melphalan-prednisone + thalidomide over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract no. 1]J Clin Oncol, 24
F. DeMarinis, S. Paul, N. Hanna (2006)
Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer [abstract no. 7133]J Clin Oncol, 24
T. Facon, J. Mary, C. Hulin, L. Benboubker, M. Attal, M. Renaud, J. Harousseau, B. Pégourié, G. Guillerm, C. Chaleteix, M. Dib, L. Voillat, H. Maisonneuve, J. Troncy, V. Dorvaux, M. Monconduit, Claude Martin, P. Casassus, J. Jaubert, H. Jardel, B. Kolb, F. Bauters (2005)
Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.Blood, 106
D.L. Wickerham, J.P. Costantino, V. Vogel (2006)
The Study of Tamoxifen and Raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study [abstract no. LBA5]J Clin Oncol, 24
D. Cunningham, S. Rao, N. Starling (2006)
Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: the REAL 2 trial [abstract no. LBA4017]J Clin Oncol, 24
G. Hudes, M. Carducci, P. Tomczak (2006)
A phase 3, randomized, 3-arm study of temsirolimus or interferon-alpha or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma [abstract no. LBA4]J Clin Oncol, 24
Am J Cancer 2006; 5 (4): 273-284 MEETING REPORT 1175-6357/06/0004-0273/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. The 42nd Annual Meeting of The American Society of Clinical Oncology (ASCO) 2–6 June 2006, Atlanta, Georgia, USA William Stow and Michelle I. Wilde Adis International Inc., Yardley, Pennsylvania, USA The 42nd Annual Meeting of the American Society of Clinical Addition of lapatinib to capecitabine almost doubles time to Oncology (ASCO) was held in Atlanta, Georgia, USA, in June progression compared with capecitabine alone in women with 2006. This year’s theme was ‘Advocating Survivorship, Clinical HER2-positive, trastuzumab-refractory, advanced breast cancer, Science, and Oncology Quality Care’. ASCO is always a highlight according to interim results of the EGF100151 trial that were on oncologists’ calendars and is consistently a premier source of presented as late-breaking data at a scientific special session by Dr high-impact clinical trial data. Interest was particularly high this Charles Geyer of Allegheny General Hospital (Pittsburgh, PA, year in the treatment of patients who have become refractory to USA). This international, randomized, phase III trial enrolled 392 existing medications. There were >4400 abstracts presented; this women, 321 of whom were evaluable for the primary endpoint of represents a 12–15%
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.